UKHSA Taps Sleep Cycle Data in Bid to Improve Early Detection of Respiratory Outbreaks

The latest announcement is out from Sleep Cycle AB ( (SE:SLEEP) ).

The UK Health Security Agency (UKHSA) and Sleep Cycle have launched a 12-week research collaboration to assess whether anonymised, privacy-preserved data from the Sleep Cycle app and its Cough Radar tool can complement traditional respiratory disease surveillance in England. By comparing sleep-based signals, such as nighttime coughing intensity, against existing hospital and surveillance data for respiratory viruses including influenza, RSV and Covid-19, UKHSA aims to determine if sleep app data can provide earlier warning of rising infection rates. The project marks UKHSA’s first systematic evaluation of sleep app data for national epidemiological monitoring and underscores Sleep Cycle’s strategic evolution from a consumer-focused app to a contributor to population-level health research, potentially enhancing early-warning capabilities and demonstrating the value of responsibly used digital health data for public benefit.

The most recent analyst rating on (SE:SLEEP) stock is a Buy with a SEK28.00 price target. To see the full list of analyst forecasts on Sleep Cycle AB stock, see the SE:SLEEP Stock Forecast page.

More about Sleep Cycle AB

Sleep Cycle AB is a Swedish digital health company that operates a consumer sleep-tracking app designed to help users develop healthier sleep habits, identify potential sleep issues, and analyse sleep patterns using patented sound technology. With over 3 billion analysed sleep sessions across 180 countries, the Nasdaq Stockholm-listed company also offers corporate partnerships, SDK solutions and access to an extensive sleep data library, positioning itself as a provider of sleep-related insights and solutions for businesses and public-health collaborators.

Average Trading Volume: 32,489

Technical Sentiment Signal: Sell

Current Market Cap: SEK482.6M

See more insights into SLEEP stock on TipRanks’ Stock Analysis page.